The most difficult problem at present is the selection of effective therapy of chronic autoimmune urticaria (CAU) because treatment with antihistamines doesn't give complete control over the disease.
Methods: immunological, clinical
Results:
The objective of this work was the studying of efficacy of intravenous immunoglobuline “Gabriglobin” in this patients` category. Patients with CAU (34 subjects) were treated with drip-feed injections of “Gabriglobin” in the dose 2,5 mg per day for 4 days.
Criteria of efficacy evaluation were the dynamics of clinical symptoms (changes of autoserum skin prick test diameters, wheals` quantity dynamics, itching intensity changes and remission duration) and laboratory indices. Among the patients treated with Gabriglobin, the good result of treatment was noted more frequently (38,23%), excellent result of treatment was noted slightly more rare (26,47%), satisfactory and unsatisfactory results were observed in 17,65 % of cases.
Effect of “Gabrigolobin” may be caused by several mechanisms.
For the first time there have been revealed the positive regulating influence of “Gabrigolobin” on dynamics of a number of laboratory indicators such as interleukins IL-4, IL-10, γ-INF, С3 and С4 complement components, anti-DNA antibodies, and also anti-thyroperoxidase antibodies level.
Conclusions:
Intavenous immunoglobulin “Gabriglobin” use should be considered as a priority guideline in the CAU therapy.